Use of Eculizumab in a kidney transplant receptor with high levels of donor-specific anti-HLA preformed antibodies
Abstract
We present a case in which, for the first time in Latin America, eculizumab, a antibody that inhibits terminal activation of the complement, for the prevention of antibody-mediated rejection (RMA) in a kidney transplant recipient with high titres of donor-specific anti-HLA antibodies preformed The patient, a man of 51 years of age, transplanted for the second time, receiver of a related living donor graft, received, before the transplant, four sessions of plasmapheresis and therapy with tacrolimus and mycophenolate sodium until the day of transplant. The induction therapy was with immunoglobulin Antithymocyte and intravenous immunoglobulin (IVIg). The administration of eculizumab was as follows: 1200 mg. two hours before of the transplant; 600 mg within the first 24 hours after the transplant; for a month,
once a week, 600 mg. At day 30, one dose of 1200 mg. One month after the transplant, the patient shows good graft function.
References
Port FK, Wolfe RA, Mauger EA, Berling DP, Jiang K. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993;270(11):1339-43.
Lonze BE, Dagher NN, Simpkins CE, Locke JE, Singer AL, Segev DL, et al. Eculizumab, bortezomib and kidney paired donation facilitate transplantation of a highly sensitized patient without vascular access. Am J Transplant. 2010;10(9):2154-60.
Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol. 2012;8(6):348-57.
Stegall MD, Diwan T, Raghavaiah S, Cornell LD, Burns J, Dean PG, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant. 2011;11(11):2405-13.
Yabu JM, Pando MJ, Busque S, Melcher ML. Desensitization combined with paired exchange leads to successful transplantation in highly sensitized kidney transplant recipients: strategy and report of five cases. Transplant Proc. 2013;45(1):82-7.
Parker C. Eculizumab for paroxysmal nocturnal haemoglobinuria. Lancet. 2009;373(9665):759-67.
Kim JS, Lee JW, Kim BK, Lee J-H, Chung J. The use of the complement inhibitor eculizumab (Soliris®) for treating Korean patients with paroxysmal nocturnal hemoglobinuria. Korean J Hematol. 2010;45(4):269-74.
Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol. 2011;3:5-12.
Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant
patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant. 2009;9(11):2644-5.
Schmidtko J, Peine S, El-Housseini Y, Pascual M, Meier P. Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: a focus on eculizumab. Am J Kidney Dis. 2013;61(2):289-99.
Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, et al. Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation. Am J Transplant. 2011;11(11):2523-7.
Peffault de Latour R, Xhaard A, Fremeaux-Bacchi V, Coppo P, Fischer AM, Helley D, et al. Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy. Br J Haematol. 2013;161(2):279-80.
Noone D, Al-Matrafi J, Tinckam K, Zipfel PF, Herzenberg AM, Thorner PS, et al. Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. Am J Transplant. 2012;12(9):2546-53.
González-Roncero F, Suñer M, Bernal G, Cabello V, Toro M, Pereira P, et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc. 2012;44(9):2690-4.
Morath C, Opelz G, Zeier M, Süsal C. Prevention of antibody-mediated kidney transplant rejection. Transpl Int. 2012;25(6):633-45.
